Prøve GULL - Gratis
The startups betting you can quit GLP-1s and stay thin
Fortune US
|DEEP DIVES: Special Digital Issue
Some weight-loss companies are marketing Ozempic and Wegovy as a short-term holy grail. Doctors say it doesn't work that way.
"Ozempic doesn't have to be forever."
It's a line that may appear on your social media feeds if you've googled how to lose weight, or read up on Hollywood's latest miracle drug: Ozempic. The pink ad, posted as part of a campaign on Reddit, Instagram, and Facebook in recent months by the $3.7 billion weight-loss startup Noom, shows the drug's blue syringe pen moving back and forth below a timeline that doesn't extend beyond a year.
What the ad promises is nothing short of the holy grail of the $90 billion U.S. diet industry, the cure that Americans, especially American women, have sought for generations and are willing to pay dearly for: a new, more slender you, hassle-free. Quick weight loss, then a return to your familiar life-thinner, healthier, and happier.
It's no wonder that, since this new class of appetite-curbing GLP-1 medications, including Ozempic, Wegovy, and Zepbound, burst into public consciousness, nearly $1 billion of venture capital dollars have been injected into the growing sector of weight-loss companies, which is now awash with startups prescribing the drugs, according to PitchBook data from the past year and a half.
It's true that these medicines appear to be startlingly effective for weight loss, a game changer for many people with obesity. But the second part of what some startups prescribing these medications promise-the "doesn't have to be forever" part, or the notion that these drugs can "reset" your metabolism-is far more contentious. As the drug manufacturers Novo Nordisk and Eli Lilly have made exceedingly clear, these medicines are intended as long-term commitments, like medication for high blood pressure. They are not meant to be taken temporarily. Indeed, seven doctors who spoke with Fortune say the preponderance of medical trials so far show that, generally, people who stop taking the drugs regain most of the weight they’ve lost within about a year.
Denne historien er fra DEEP DIVES: Special Digital Issue-utgaven av Fortune US.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Fortune US
Fortune US
MCKINSEY ALUMS DOMINATE THE WORLD'S C-SUITES. WILL AI DRY UP THE FIRM’S CEO PIPELINE?
THE CONSULTING GIANT HAS PRODUCED MORE FORTUNE 500 CEOs THAN ANY OTHER INSTITUTION. NOW IT'S SPRINTING TO RETHINK HOW IT TRAINS LEADERS.
15 mins
October - November 2025
Fortune US
WANNA BET? WHY INVESTORS ARE GAMBLING ON KALSHI AND POLYMARKET
THE 2024 ELECTIONS SHOWED THE POTENTIAL AND POPULARITY OF “PREDICTION MARKETS.” BUT THE STARTUPS AND THEIR HEADSTRONG YOUNG FOUNDERS STILL FACE LONG ODDS.
13 mins
October - November 2025
Fortune US
RESTORING THE AURA OF RALPH LAUREN
A DECADE AGO, RALPH LAUREN THE COMPANY WAS JEOPARDIZING ITS LUXURY REPUTATION AND WATCHING PROFITS PLUMMET. THE SOLUTION: FINDING THE RIGHT PARTNER FOR RALPH LAUREN, THE MAN. HOW PATRICE LOUVET HELPED AMERICA’S MOST IMPORTANT FASHION COMPANY GET ITS GROOVE BACK.
13 mins
October - November 2025
Fortune US
RAMP WANTS TO SHAKE UP CORPORATE CREDIT CARDS. INVESTORS BELIEVE THAT'S A $22.5 BILLION IDEA
The fintech startup is aspiring to change the way companies spend—and taking aim at American Express. But can Ramp live up to the hype?
13 mins
October - November 2025
Fortune US
PASSIONS: BE OUR (ONLY) GUEST
AFTER THE MANGOSTEEN daiquiri misted tableside with lime oil, the cheesy garlic naan, the broccoli salad with pistachios and mint, the pink peppered pineapple soda, the tandoori half-chicken with tingling green chutney, the crock of thick, savory, buttery black dal—after all that, served in the celadon-green Permit Room in Notting Hill, no, I did not need dessert.
3 mins
October - November 2025
Fortune US
THE BATTLE TO SAVE INTEL
BUOYED BY EMERGENCY INVESTMENTS FROM THE U.S. GOVERNMENT AND INDUSTRY PEERS, ONE OF AMERICAʼS GREATEST TECH COMPANIES IS IN THE FIGHT OF ITS LIFE.
10 mins
October - November 2025
Fortune US
THE FUTURE 50: FAST-GROWING COMPANIES THAT INVESTORS SHOULD WATCH—AND LEADERS SHOULD EMULATE
BUSINESSES WORLDWIDE have weathered a chaotic year so far in 2025. Shifting global trade and tariff dynamics and the AI race have made the pace of change even more relentless than usual. Costs have risen, and bankruptcies are up. Still, across sectors, some companies are not just staying afloat, but thriving—and in many markets, buoyant share prices show that investors retain their optimism.
4 mins
October - November 2025
Fortune US
FEAR ON THE FARM
BIG AGRICULTURE WRESTLES WITH THE WHITE HOUSE IMMIGRATION CRACKDOWN.
10 mins
October - November 2025
Fortune US
TECH: THE AI OF THE HURRICANE
WHEN NASA and its Soviet rivals launched the first meteorological satellites into space in the 1960s, weather forecasts on Earth changed forever. With a constellation of eyes in the sky, forecasters could suddenly monitor conditions over oceans and remote landmasses, filling in major gaps in their models and providing an early warning system about potential storms forming far away.
4 mins
October - November 2025
Fortune US
WHEN THE MACHINES CAME FOR AMERICAN JOBS
“FARM MECHANIZATION HAS JUST BEGUN,” proclaimed the cover of Fortune's October 1948 edition. And indeed, the rise of machines such as the tractor was causing profound changes in the American workforce, the accompanying article explained: “In 1800 three out of four in the working population were in agriculture... In 1948 only one in seven U.S. workers is needed to provide the nation’s food.” That trend continued: In 2003, Fortune reported that the agricultural workforce made up just 2% of employment—yet farms still produced a more-than-adequate bounty for American consumption and export.
1 min
October - November 2025
Listen
Translate
Change font size
